Avanos Medical Statistics
Total Valuation
Avanos Medical has a market cap or net worth of $605.80 million. The enterprise value is $647.38 million.
Important Dates
The last earnings date was Tuesday, May 6, 2025, before market open.
| Earnings Date | May 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Avanos Medical has 46.24 million shares outstanding. The number of shares has decreased by -1.13% in one year.
| Current Share Class | 46.24M |
| Shares Outstanding | 46.24M |
| Shares Change (YoY) | -1.13% |
| Shares Change (QoQ) | +1.74% |
| Owned by Insiders (%) | 1.86% |
| Owned by Institutions (%) | 83.91% |
| Float | 42.37M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 11.80 |
| PS Ratio | 0.84 |
| Forward PS | 0.87 |
| PB Ratio | 0.70 |
| P/TBV Ratio | 2.18 |
| P/FCF Ratio | 5.29 |
| P/OCF Ratio | 4.49 |
| PEG Ratio | 2.07 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 6.90, with an EV/FCF ratio of 5.68.
| EV / Earnings | n/a |
| EV / Sales | 0.94 |
| EV / EBITDA | 6.90 |
| EV / EBIT | 12.92 |
| EV / FCF | 5.68 |
Financial Position
The company has a current ratio of 2.57, with a Debt / Equity ratio of 0.17.
| Current Ratio | 2.57 |
| Quick Ratio | 1.47 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | 1.31 |
| Debt / FCF | 1.24 |
| Interest Coverage | 4.47 |
Financial Efficiency
Return on equity (ROE) is -36.78% and return on invested capital (ROIC) is 2.58%.
| Return on Equity (ROE) | -36.78% |
| Return on Assets (ROA) | 2.26% |
| Return on Invested Capital (ROIC) | 2.58% |
| Return on Capital Employed (ROCE) | 5.16% |
| Revenue Per Employee | $309,475 |
| Profits Per Employee | -$172,699 |
| Employee Count | 2,227 |
| Asset Turnover | 0.50 |
| Inventory Turnover | 2.06 |
Taxes
| Income Tax | -14.90M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.09% in the last 52 weeks. The beta is 1.14, so Avanos Medical's price volatility has been higher than the market average.
| Beta (5Y) | 1.14 |
| 52-Week Price Change | -33.09% |
| 50-Day Moving Average | 13.54 |
| 200-Day Moving Average | 18.39 |
| Relative Strength Index (RSI) | 53.72 |
| Average Volume (20 Days) | 526,228 |
Short Selling Information
The latest short interest is 1.13 million, so 2.45% of the outstanding shares have been sold short.
| Short Interest | 1.13M |
| Short Previous Month | 723,475 |
| Short % of Shares Out | 2.45% |
| Short % of Float | 2.67% |
| Short Ratio (days to cover) | 2.24 |
Income Statement
In the last 12 months, Avanos Medical had revenue of $689.20 million and -$384.60 million in losses. Loss per share was -$8.37.
| Revenue | 689.20M |
| Gross Profit | 376.30M |
| Operating Income | 50.10M |
| Pretax Income | 14.70M |
| Net Income | -384.60M |
| EBITDA | 93.80M |
| EBIT | 50.10M |
| Loss Per Share | -$8.37 |
Full Income StatementBalance Sheet
The company has $97.00 million in cash and $140.90 million in debt, giving a net cash position of -$43.90 million or -$0.95 per share.
| Cash & Cash Equivalents | 97.00M |
| Total Debt | 140.90M |
| Net Cash | -43.90M |
| Net Cash Per Share | -$0.95 |
| Equity (Book Value) | 839.40M |
| Book Value Per Share | 18.15 |
| Working Capital | 215.20M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $134.40 million and capital expenditures -$20.40 million, giving a free cash flow of $114.00 million.
| Operating Cash Flow | 134.40M |
| Capital Expenditures | -20.40M |
| Free Cash Flow | 114.00M |
| FCF Per Share | $2.47 |
Full Cash Flow StatementMargins
Gross margin is 54.60%, with operating and profit margins of 7.27% and -55.80%.
| Gross Margin | 54.60% |
| Operating Margin | 7.27% |
| Pretax Margin | -57.33% |
| Profit Margin | -55.80% |
| EBITDA Margin | 13.61% |
| EBIT Margin | 7.27% |
| FCF Margin | 16.54% |